Cover Image
Market Research Report

Physician Perspectives 2017: Biosimilar use in IBD

Published by GlobalData Product code 721700
Published Content info 54 Pages
Delivery time: 1-2 business days
Back to Top
Physician Perspectives 2017: Biosimilar use in IBD
Published: February 1, 2018 Content info: 54 Pages

This Physician Perspectives survey focuses on the use of biosimilar anti-TNFs in IBD.

In the next 12 months, nearly half of physicians stated that they would consider switching Remicade patients (in remission) over to biosimilar IFX. A large proportion of physicians reported that their patients have at least occasionally expressed concern (rated >3) over being switched onto a biosimilar anti-TNF from an originator anti-TNF (67%) or being prescribed a biosimilar anti-TNF (54%). Overall, the majority of physicians agreed that they would require a biosimilar to be designated as interchangeable before considering switching patients from an originator to a biosimilar (67%).

The report includes following topics -

  • Familiarity with biosimilar IFX
  • Expected use of biosimilars - IFX & ADA
  • Concerns with biosimilars
  • Switching & Interchangeability.


  • Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
  • Physicians interviewed were from 5EU and US countries > This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.

Reasons to buy

  • Qualitative insight from 100 high-prescribing specialists in IBD
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Table of Contents
Product Code: GDHC002SP

Table of Contents

Executive Summary


Survey Results



Back to Top